Nuvo Pharmaceuticals Inc. (NRI.TO)


Toronto - Toronto Delayed Price. Currency in CAD
7.15+0.10 (+1.42%)
At close: 3:54 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open7.00
Prev Close7.05
Bid7.15 x
Ask7.45 x
Day's Range6.95 - 7.20
52wk Range3.77 - 8.35
1y Target EstN/A
Market Cap82.25M
P/E Ratio (ttm)1,430.00
Beta-0.39
Volume26,724
Avg Vol (3m)16,746
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • CNW Group29 days ago

    Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial Officer

    Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial Officer

  • CNW Group29 days ago

    Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer

    Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer

  • PR Newswire29 days ago

    Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer

    MISSISSAUGA, ON, Sept. 1, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (NRI.TO), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer.  Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller.  She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration  Degree from the Ivey Business School, University of Western Ontario.  Ms. Burkett replaces Stephen Lemieux who has resigned to pursue other opportunities. "Mary-Jane has been, and in her new role, will continue to be an integral part of the Nuvo Pharma executive team," said John London, President and CEO of Nuvo.  "We are grateful for Stephen's significant contributions to Nuvo since he joined us in 2007, and wish him success in his future endeavours.